You guys and myself need to give Evoke Pharma Inc a little more time to get something together. It has only been a week ago since we received the press release the FDA approve NDA for Gimoti (metoclopramide) Nasal Spray to treat Diabetic Gastroparesis. The Board members and CEO is not sitting around and doing nothing with an approve high quality advance Diabetic Gastroparesis therapeutic treatment the first of its kind in a nasal spray worth Billions in prescription sales. Last Friday June 19, 2020 the FDA approve EVoke's Pharma inc Drug Gimoti nasal spray for commercial prescription use in a $4 billion prescription sales market with only 1 real competitor treating Gastroparesis disease with a pill form of metoclopramide. No one else can't sale the Nasal Spray form of Metoclopramide it is patent until 2030. So Evoke alone can sale nasally use form of metoclopramide.
Whether Evoke Pharma sale the company or Let Eversana Science Manufacture Gimoti Nasal Spray, commercialize, handle distribution, handle sales using their own professional sales team, and patients insurance and re-imbursements. this will be the duties of Eversana. In return Everana Science will receive 20% of Gimoti (metoclopramide) nasal spray profits, and Evoke Pharma inc will get 80% of Gimoti (metoclopramide) nasal spray profits. As of last week Friday Evoke Pharma is eligible for a $5 million dollar line of credit from Eversana.
Evoke Pharma had in the PR Gimoti will be market in the 4th quarter this year. To some that might seem like a long time 3 more full months before 4th quarter, but it is not. Evoke and Eversana need time to do all the duties mention in this second paragraph above. I'm just going to be adding while the share price is still more affordable to buy for my money a few shares at a time each pay period or from sells of other stocks.
Good Luck to all us Evoke shareholders soon to be millionaires.
